SSTR2 and small cell lung carcinoma: In patients with SCLC, however, molecular imaging with SSTR2-agonists yielded inconsistent results with high PET tracer accumulation only in selected subgroups of patients 13, and SSTR2-agonist PRRT has not found its way into clinical practice.